Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · March 01, 2016

New Abdominal Mets in RCC Patient: What is the 2nd Line Treatment?

Heather Greene MSN, FNP, AOCNP

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Heather Greene MSN, FNP, AOCNP

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bradley Somer MD

    Bradley G. Somer MD

    Feb 03, 2016

    He has had approximately 17 month PFS on Votrient for papillary RCC. He seemed to have had a good and durable response. Upon progression, there is no clear standard. NCCN lists no clear consensus second line standard therapy for non-clear cell. Checkmate-025, where nivolumab is expected to do better than on mTOR inhibitors:  http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510665  included only clear cell carcinoma. He would be a candidate for the checkmate-374 study which is a ph3/4 of nivolumab and includes potentially non-clear cell histology. Other trials which he may be eligible for is an AR positive basket trial. There is some pre-clinical data on AR in kidney cancer and perhaps SARM could be a strategy that could be investigated in AR + patients on clinical trials.  

  • Angel Rodriguez

    May 05, 2016

    Without evindence, a option can be axitinib due to good response in first line with one tki

  • Amanullah Memon

    May 13, 2016

    in absence of clear consensus on standard therapy for papillary RCC 17 month PFS makes Votrient a credible choice.

  • Jan 07, 2025

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated